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Polymethoxylavones (PMFs) are known to exhibit significant anti-inflammatory
and neuroprotective properties. Nicotiana plumbaginifolia, an annual Bangladeshi
herb, is rich in polymethoxyflavones that possess significant analgesic and
anxiolytic activities. The present study aimed to determine the antinociceptive and
neuropharmacological activities of polyoxygenated flavonoids namely- 3,3′,5,6,7,
8-hexamethoxy-4′,5′-methylenedioxyflavone (1), 3,3′,4′,5′,5,6,7,8-octamethoxyflavone
(exoticin) (2), 6,7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone (3), and 3,3′,4′,5,5′,
8-hexamethoxy-6,7-methylenedioxyflavone (4), isolated and identified from
N. plumbaginifolia. Antinociceptive activity was assessed using the acetic-acid induced
writhing, hot plate, tail immersion, formalin and carrageenan-induced paw edema
tests, whereas neuropharmacological effects were evaluated in the hole cross, open
field and elevated plus maze test. Oral treatment of compounds 1, 3, and 4 (12.5–25
mg/kg b.w.) exhibited dose-dependent and significant (p < 0.01) antinociceptive
activity in the acetic-acid, formalin, carrageenan, and thermal (hot plate)-induced pain
models. The association of ATP-sensitive K+ channel and opioid systems in their
antinociceptive effect was obvious from the antagonist effect of glibenclamide and
naloxone, respectively. These findings suggested central and peripheral antinociceptive
activities of the compounds. Compound 1, 3, and 4 (12.5 mg/kg b.w.) demonstrated
significant (p < 0.05) anxiolytic-like activity in the elevated plus-maze test, while the
involvement of GABAA receptor in the action of compound 3 and 4 was evident from
the reversal effects of flumazenil. In addition, compounds 1 and 4 (12.5–25 mg/kg
b.w) exhibited anxiolytic activity without altering the locomotor responses. The present
study suggested that the polymethoxyflavones (1–4) from N. Plumbaginifolia could
be considered as suitable candidates for the development of analgesic and anxiolytic
agents.
Keywords: Nicotiana plumbaginifolia, polymethoxyflavone, antinociceptive, opioid, anxiolytic, benzodiazepine
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INTRODUCTION
Pain is an unpleasant sensory perception accompanied byQ6
physiological damage comprising actual or potential tissue injury
(de Sousa, 2011). Such sensation also relies on individual’s
emotional state and can be exacerbated by the psychological
disorders like anxiety and depression. It adversely affects the
quality of life and is one of the common reasons for visiting
physicians and taking medications (de Santana et al., 2015).
However, conventional medicines such as non-steroidal anti-
inflammatory drugs (NSAIDs), steroids, and opioid analgesics
are associated with significant side effects including gastric
ulcers, dependence and depression, making drug therapies more
complex and difficult (Poetker and Reh, 2010; Tiwari and Singh,
2014).
Medicinal plants serve as a major source of pharmacologically
active compounds that are used in the treatment of human
diseases like pain and psychiatric disorders such as anxiety
and depression (McCurdy and Scully, 2005; Bouayed, 2010;
Saki et al., 2014). Polymethoxyflavones (PMFs) are exclusively
found in citrus peels (Li et al., 2009) and some other
pharmacologically significant plants (Kinoshita and Firman,
1996; Chen et al., 2011; Faqueti et al., 2016). They belong
to the superfamily of flavonoids which can be classified as
anthoxanthins (e.g., flavones, flavonols), flavanones, flavanonols,
flavans, and anthocyanidins. PMFs are termed as flavones which
contain more than one methoxy (-O-CH3) groups on their
essential benzo-γ-pyrone skeleton, generally constituted by 15
carbons (C6-C3-C6), including a carbonyl group (C=O) at C-
4 position (Ververidis et al., 2007; Li et al., 2008). Scientific
studies revealed that PMFs might exert prominent in vivo or in
vitro anti-nociceptive (Nadipelly et al., 2016), anti-inflammatory,
anticarcinogenic (Li et al., 2009), cancer chemopreventive (Walle,
2007), sedative (Jin et al., 2012), anti-depressant, anxiolytic as
well as benzodiazepine binding effects (Paladini et al., 1999;
Abdelhalim et al., 2015) and possess excellent absorption and oral
bioavailability (Li et al., 2009).
Nicotiana plumbaginifolia Vivane (Fam. Solanaceae) is a
flowering annual herb of Bangladesh. It is used in the treatment
of cuts, wounds, toothache, rheumatic swelling in thetraditional
system of medicines (Dangwal et al., 2010; Singh et al.,
2010; Devi et al., 2014). Pharmacological studies showed that
leaves of this plant possess significant analgesic and anxiolytic
activities (Shahriar et al., 2015). Phytochemical analysis of
Abbreviations: PMFs, Polymethoxyflavones; NSAIDs, non-steroidal anti-
inflammatory drugs; ATP, Adenosine triphosphate; Na-CMC, sodium
carboxymethyl cellulose; OECD, Organization for Economic Cooperation
and Development; AVMA, American Veterinary Medical Association; icddr,b,
International Center for Diarrhoeal Disease Research; b.w., body weight; p.o.,
per oral; i.p. intraperitoneal; µL, microliter; mL, milliliter; cm, centimeter; mg,
milligram; kg, kilogram; MA, mean ambulation; MPE, maximal possible analgesic
effect; AUC, area under the curve; min, minimum; max, maximum; n, number of
mice; NLX, naloxone; Gbc, glibenclamide; Flu, flumazenil; PG, prostaglandin; NO,
nitric oxide; iNOS, Inducible nitric oxide synthase; CASP6, Caspase-6 precursor;
cGMP, cyclic guanosine monophosphate; PG, prostaglandin; LOX, lipoxygenase;
COX, cyclooxygenase; TNF-α, Tumor necrosis factor alpha; IL-8, Interleukin 8;
IL-1β, Interleukin-1 beta; GABA, gamma aminobutyric acid; CNS, central nervous
system.
the leaves of this plant afforded PMFs namely- 3,3′,5,6,7,
8-hexamethoxy-4′,5′-methylenedioxyflavone (1), 3,3′,4′,5′,5,6,7,
8-octamethoxyflavone (exoticin) (2), 6,7,4′,5′-dimethylenedioxy-
3,5,3′-trimethoxyflavone (3), and 3,3′,4′,5,5′,8-hexamethoxy-
6,7-methylenedioxyflavone (4). However, there is no report
on the pharmacological actions of the PMFs isolated from
N. plumbaginifolia. Therefore, based on the pharmacologically
relevant reports of PMFs from other sources, and extractives
of N. plumbaginifolia, PMFs from this plant were evaluated for
their antinociceptive activity in the acetic acid-induced writhing,
hot plate, tail immersion, formalin-induced nociception, and
paw edema and carrageenan-induced paw edema test and
neuropharmacological effect in open field, elevated plus maze
test on mice. Experimental study along with deciphering the
mechanism of actions of the experimental drugs or compounds
in the living system is an important part of analytical and
experimental pharmacology as well as the discovery of new
therapeutic agents (Salomone, 2010). The involvement of
opioid, ATP-sensitive K+ channel in the antinociceptive and
benzodiazepine system in the anxiolytic action of the isolated
PMFs were also determined in this study.
MATERIALS AND METHODS
Isolation and Characterization of
Experimental Compounds
Repeated chromatographic separation and purification of
Q7
the methanol (MeOH) extract of N. plumbaginifolia leaves
led to the isolation and characterization of 3,3′,5,6,7,8-
hexamothoxy-4′,5′-methylenedioxyflavone (1), 3,3′,4′,5′,5,6,7,
8-octamethoxyflavone (exoticin) (2), 6,7,4′,5′-dimethylenedioxy-
3,5,3′-trimethoxyflavone (3), and 3,3′,4′,5,5′,8-hexamethoxy-6,7-
methylenedioxyflavone (4) (Figure 1), the experimental details
and structural data of which are available in the literature (Shajib
et al., 2017).
Drugs and Reagents
Acetic acid, potassium hydroxide (Merck Co., Darmstadt,
Germany),methanol, lambda (λ)- carrageenan, formalin,
pentobarbital sodium, sodium carboxymethylcellulose (Na-
CMC) (Sigma, St. Louis, MO, USA), morphine sulfate
(Gonoshasthaya Pharmaceuticals Ltd., Savar, Dhaka,
Bangladesh), diclofenac sodium (Novartis Bangladesh Ltd.,
Gazipur, Dhaka, Bangladesh), naloxone hydrochloride (Hospira
Australia Pty Ltd, Melbourne, Australia), glibenclamide (Square
Pharmaceuticals Ltd., Gazipur, Dhaka, Bangladesh), diazepam
(Square Pharmaceuticals Ltd., Gazipur, Dhaka, Bangladesh),
flumazenil (Roche Bangladesh Pharmaceuticals Ltd., Dhaka,
Bangladesh), physiological saline (sodium chloride 0.9% w/v)
(Beximco Pharmaceuticals Ltd, Tongi, Dhaka, Bangladesh) were
either purchased or obtained as gifts.
Ethical Declarations
The animals were treated according to the protocols of the
Ethical Principles and Guidelines of Scientific Experiments
on Animals (1995) recommended by the Swiss Academy of
Medical Sciences and the Swiss Academy of Sciences. The acute
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FIGURE 1 | Polymethoxyflavones (PMFs) of N. plumbaginifolia. 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = 3,3′,4′,5′,5,6,7,Q4 Q5
8-octamethoxyflavone (exoticin); 3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone.
oral toxicity was determined according to the recommendation
(420- fixed dose procedure) of Organization for Economic
Cooperation and Development (OECD). After experiments,
the animals were subjected to euthanasia using pentobarbital
following AVMA Guidelines for the Euthanasia of Animals of
2013 edition. All experimental methods and principles were
endorsed by the Ethics Committee of Stamford University
Bangladesh (SUB/IAEC/15.03). Every effort was taken to alleviate
the potential sufferings of the animals.
Animals
Pharmacological investigations were conducted on 20–25 g, 8–
10 weeks old healthy male Swiss albino mice. The animals were
obtained from the Animal Resources Branch of the International
Center for Diarrhoeal Disease Research, Bangladesh (icddr,b).
The procured animals were rehabilitated in 120 × 30 ×
30 cm cages with wood shavings bedding, kept under controlled
laboratory condition of 24 ± 2◦C temperature, 55–60% relative
humidity and 12-h light–dark cycle (light on 7:00 a.m. to 7:00
p.m.). They had free access to standard diet and water ad
libitum. They were acclimatized in the laboratory environment
for 14 days prior to the investigations. The healthcondition of
the animals was checked regularly. The animals were randomly
chosen and allocated into negative control, positive control,
and experimental group. Each group had six animals (n = 6).
Investigators, who were responsible for recording data, were
unaware of the assigned group to avoid any experimental bias.
The test animals did not have any access to food 3–4 h prior to the
commencement of the experiments and experimentations were
carried out between 9:00 a.m. and 5:00 p.m.
Treatments
Animals of experimental groups were treated with single oral
dose 12.5 or 25 mg/kg b.w. of the isolated compounds. The
doses were selected based on pilot experiment and previously
reported oral effective doses of PMFs (Jang et al., 2013). All
experimental doses were formulated with physiological saline
containing 0.5% Na-CMC. The control group was treated
per oral (p.o) with 0.5% Na CMC as vehicle at the dose
of 10 mL/kg b.w. The vehicle and experimental PMFs were
administered 60min before the experiments. PMFs have been
reported to possess excellent absorption and oral bioavailability
properties (Li et al., 2009), and are effective after 1 h of oral
administration (Jin et al., 2012). The pharmacokinetics of drugs
from oral treatment is considered to be similar to that of
intraperitoneal (i.p.) treatment (Turner et al., 2011). Therefore,
the oral effect of experimental PMFs has been compared with the
intraperitoneally (i.e., parenteral) administered standard drugs.
For the antinociceptive tests, morphine sulfate, and diclofenac
sodium were used as positive control drugs at the dose of 5- and
10-mg/kg b.w., respectively. Since parenteral drugs have quicker
onset of action compared to oral administration of (Turner
et al., 2011) standard drugs, diclofenac (i.p.) or morphine (i.p.)
were administered 30min before the experiments. In the hot
plate and tail immersion tests, naloxone was employed (i.p.) at
the dose of 2 mg/kg b.w., 15min before the administration of
morphine sulfate or isolated compound to verify the possible
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involvement of opioid system. To evaluate the association of
ATP-sensitive K+ channel in the analgesic effect, glibenclamide
(Gbc), an ATP-sensitive K+ channel blocker, was administered at
the dose of 10-mg/kg b.w. (i.p.), 15min prior to administration
of the isolated compound in the acetic acid-induced writhing
test. Diazepam was used as the positive control in the hole
cross, open field, and elevated plus maze test at 1 mg/kg (i.p.)
b.w. 30min prior to the commencement of the experiments.
The participation of benzodiazepine receptor in the anxiolytic
effect was justified using flumazenil, a selective benzodiazepine
antagonist of GABAA receptor, at the dose of 2.5 mg/kg (i.p.),
15min before the administration of the plant isolates or diazepam
in elevated plus maze test.
Safety Evaluation (Acute Toxicity Test)
The selected doses (12.5–25 mg/kg, b.w.) of the experimental
compounds were administered into the animals following
the guidelines (420 fixed dose procedure) recommended by
Organization for Economic Cooperation and Development
(OECD) for acute toxicity study. Experimental animals were
allocated into a control and eight test groups. Six animals were
selected for each group (n = 6). Control and experimental
group animals received single oral dose of vehicle (1% Na-
CMC, 10 mL/kg b.w.) and test compound (12.5 or 25 mg/kg
b.w.) respectively. The animals abstained from feed and water
2 h prior to treatment with vehicle or test compounds. After
oral gavage, each group of mice was separately housed and
had access to feed and water ad libitum. The animals were
then observed occasionally for the next 24 h and daily for a
total of 14 days. During this period, animals were observed for
mortality, aberrant behavior, salivation, tremors, convulsion, and
any abnormalities regarding food consumption, eyes (irritation
or discharges), hair, skin (irritation, rashes, swelling or itching),
and feces (physical appearance and bowel movements). At the
end of the observational session, the body weight of the body
weight of the animals that survived were recorded animals
was recorded. Then they were sacrificed following euthanasia
and vital organs of the body were isolated, examined for any
abnormalities and weighed to determine any significant changes
(Sehar et al., 2008; Talwar et al., 2013).
Antinociceptive Assays
Acetic Acid-Induced Writhing Test
The experiment acetic acid-induced pain, characterized by
writhing syndrome was performed to evaluate the central and
peripheral analgesic effect of the plant isolates. Experimental
mice were acclimatized in the individual experimental chamber
for 60min before the test. Each mouse received intraperitoneally
(i.p.) 1% w/v acetic acid (10 mL/kg) 60min after vehicle or
isolates and 30min after diclofenac treatment. The nociceptive
characteristics such as twisting of the trunk, elongation of the
hind limb, stretching of the abdomen induced by the noxious
stimulus were marked as writhing episodes. The time taken to
begin writhing response after acetic acid administration was
recorded as the onset of writhing. Beginning with the first
writing response, the number of writing episodes were noted in
each 10min in the 60min of the observational period (Bagdas
et al., 2016). Analgesic activity was defined as the diminishing of
writhing episodes and the percentage of inhibition of writhing
was calculated as follows:
Inhibition(%) =
Writhing of control group−
writhing of treatment group
Writhing of control group
× 100
Hot Plate Test
The experiment was carried out to measure the analgesic activity
of the compounds 1–4 against thermal pain threshold. Mice
were gently handled and placed on the heated surface of hot
plate apparatus (Eddy’s hot plate, Kshitij Innovations, Haryana,
India). The hot plate surface was covered by cylindrical glass
and temperature was kept stable at 55 ± 1◦C. The time taken
to react to the thermal nociception by responses such as licking
of the paw(s), jumping was recorded as latency time (Eddy and
Leimbach, 1953). Animals which exhibited pre-treatment latency
of 5–20 s were selected for the experiment and maximum latency
time was fixed at 20 s (cut-off time) to avoid any tissue injury.
A latency of each mouse was recorded just before treatment
(0min) and they served as a control of their own. Then latency
was recorded at 30, 45, 60, 90, and 120min following the
administration of vehicle, isolates (p.o.) or morphine (i.p.). An
increase in latency time was considered analgesic against thermal
pain. The maximal possible analgesic effect was calculated as a
percent (% MPE) from the following formula:
% MPE =
Post-treatment reaction time−
pre-treatment reaction time
20 − pre-treatment reaction time
× 100
The % MPE was plotted against time and area under the curve
(AUC0–120min) was determined by trapezoidal rule (Bhargava
et al., 1989).
Tail Immersion Test
The tail immersion test was performed to evaluate the centrally
mediated analgesia of the isolated compounds 1–4 against the
thermal nociceptive stimulus. Briefly, mice were immobilized
gently by using “chux” and 1–2 cm of the tail of each mouse was
immersed into warm water thermostatically maintained at 52 ±
1◦C (Janseen et al., 1963). The rapid flick of the tail was regarded
as the end-point of nociception and time taken to flick tail was
noted (latency time). Mice that flicked their tail between 1.5
and 3.5 s before treatment were considered for the experiment.
Then the mice were treated with vehicle, isolates or morphine
and the latency was counted after 30, 45, 60, 90, and 120min of
treatment. A 20 s cut-off time was fixed in order to prevent tissue
injury of mice. The pre-treatment latency of each mouse served
as baseline. The maximal percent of analgesia at each observation
time and (AUC0–120min) was determined as described in hot plate
test.
Formalin-Induced Nociception and Paw Edema Test
The effect of isolates against chemical-induced pain was modeled
by formalin test as the experiment is valid and frequently used
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for the evaluation of analgesic as well as anti-inflammatory
agents (Hunskaar and Hole, 1987). Mice were adapted in an
individual observational cage for 60min. The experimental mice
were gently held and pre-treated with vehicle, the plant isolates or
morphine before formalin injection. The nociception was elicited
by the treatment of 20 µL solution of 5% formalin into the
right hind paw of mice. The licking and biting of the right hind
paw by the mice were considered as responses of nociception
and time spent for showing the responses was recorded in
every 5min for total 60min of observation. The first 10min of
observation was defined as phase I or neurogenic phase and the
next 50min was Phase II or inflammatory phase. The vertical
paw thickness of each mouse was measured before and 5 h after
the treatment of formalin using a digital fine caliper (M: 091552;
Shanghai Shenhan Measuring Tools Co. Ltd., Shanghai, China).
Then edematogenic inflammatory response was calculated from
difference between the paw thickness (1) of post and pre-
formalin treatment (Wheeler-Aceto and Cowan, 1991; Xiao et al.,
2008).
Carrageenan-Induced Paw Edema Test
Anti-inflammatory effect of the isolates was studied by the
carrageenan-induced paw edema test. The experimental mice
received vehicle, experimental compounds or diclofenac and
were subjected to measure their left hind paw thickness by a
Vernier caliper before carrageenan treatment. A 25µL solution
of 1% w/v lambda carrageenan was injected deliberately under
the subplantar aponeurosis of the right hind paw of the mice
in order to induce edema (Morris, 2003). The degree of
inflammation was defined by the thickness of edema. The paw
edema thickness (1 in mm) was measured from the difference
between left hind paw thickness of before and 0, 1, 2, 3, 4, 5, and
6 h after carrageenan administration. After the observing session,
experimental mice were euthanized. The experimental paws were
dissected and soaked overnight in 2.5mL of physiological saline
at the temperature of 0–4◦C. The solution was centrifuged for
15min at 3,000 rpm to obtain as upernatant and pellet. A
volume of 0.5mL supernatant was mixed with 2mL solution
of 0.5M KOH (dissolved in MeOH) and incubated at 50◦C
for 20min. Upon cooling, the mixture was supplemented with
MeOH up to 5mL volume and thoroughly mixed. Five minutes
later the absorbance of the mixture was read at 278 nm by
UV spectrophotometer (Chopade and Sayyad, 2015). The PGE2
content was represented by optical density (OD) value of the
mixture.
Neuropharmacological Assays
Hole Cross Test
The effect of isolated compounds on the motor activity of the
mice was evaluated by the hole cross test. The experiment
was conducted following the method described by Takagi et al.
(1971). Briefly, experimental mice were pre-treated with vehicle,
compounds 1–4 or diazepam. They were individually placed in a
box (13× 14× 20 cm3), having two compartments separated by a
fixed partition. The partition contained a hole of 3 cm to facilitate
the passage for mice. The mice were placed gently facing toward
the hole in one of the compartments of the box. The transitions of
each mouse from one compartment to another were documented
for 3min. The observation was made at 0, 30, 60, 90, and 120min
following treatment and % inhibition was determined from the
transitions.
Open Field Test
Effect of the compounds on general locomotor performance was
evaluated by the open field test. The procedure was carried out
as described by Frye and Walf (2002). The open field apparatus
(76 × 57 × 35 cm3) consisted a floor divided into 48 black and
white colored square grids. Each square was colored alternatively.
The 24 perimeter squares were considered as peripheral squares
while others were central. Experimental subjects were pre-treated
with compounds 1–4, vehicle or diazepam. They were then
individually placed at the center of the floor and the number
of peripheral and central square crossed was documented for
5min. The experimentation was performed in an isolated and
sound-attenuated area. The total number of square crossed
(ambulation) was calculated and percent of central square
crossed was determined. The number of ambulation was used
to determine the % inhibition of locomotion using following
formula:
% Inhibition =
Ambulation of control group−
ambulation of treatment group
Ambulation of control group
× 100
The increase in the number of central square crossing and
percentage increase of central square crossing of mice were
regarded as anxiolytic whereas reduction of such explorations
was considered as anxiogenic (Prut and Belzung, 2003).
Elevated Plus Maze Test
The anxiolytic action of the compounds was evaluated on
elevated plus maze apparatus. The apparatus was elevated at a
height of 50 cm from the floor and consisted of two elongated
closed and open arms of equal dimensions (50 × 10 cm). The
closed arms were enclosed by side-wall of 40 cm height. Each
type of arms was arranged perpendicularly to each other. Mice
were pre-treated with vehicle, isolates, or diazepam and each
mouse was individually placed in the center of the maze facing
their head toward one of the closed arms. The number of
entries and time spent in close and open arms of the maze was
recorded for the period of 5min. The entrance of four paws
of mice into an arm was regarded as an entry. The increase
of the entries and percent entries, as well as exploration time
in open arms of mice was considered as anxiolytic, whereas
the opposite was regarded as anxiogenic (Pellow et al., 1985).
The maze was cleaned with alcohol before each experimental
session and the operation was carried out in a sound attenuated
isolated area. The % open arm time was calculated as
follows:
% of open arm time =
Time spent in open arms
Total spent time in open and closed arms
× 100
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Analysis of the Possible Mechanism of
Actions
Involvement of Opioid Receptor
To investigate the role of opioid system in the antinociceptive
action of the isolated PMFs, mice were treated with a non-
selective opioid antagonist, naloxone (2 mg/kg b.w., i.p.), 15min
before administration of the compound (25 mg/kg b.w., p.o.),
or morphine (5 mg/kg b.w., i.p.) in the tail immersion and
hot plate test. The thermal latency time of the experimental
mice was documented before the treatment of standard drug
or experimental compound and at 30, 45, 60, 90, 120min of
investigation period (Khan et al., 2011). The cut-off period was
maintained for 20 s to avoid tissue injury as described in hot plate
and tail immersion test. The documented data were assembled
with the hot plate and tail immersion test result for comparison.
Association of the ATP-Sensitive K+ Channel
Pathway
The association of ATP-sensitive K+ channel in the pain
inhibition action of the isolates in mice was evaluated as
previously described (Mohamad et al., 2011; Perimal et al., 2011).
Animals were pre-treated with glibenclamide (10 mg/kg b.w.,
i.p.), an ATP-sensitive K+ channel inhibitor 15min before the
administration diclofenac or effective dose (25 mg/kg b.w., p.o.)
of the plant isolates. Mice were treated with 1 % w/v acetic acid
(i.p.) after 60min of the isolated compounds 1–4 administration
and 30min of diclofenac. Then, time taken to start writhing
(onset time) was recorded and writhing episodes were counted in
every 10min for 60min as described in the acetic acid-induced
writhing test. These data were assembled with acid-induced
writhing test result for comparison.
Involvement of Benzodiazepine Receptor
To verify the role of benzodiazepine system in the anxiolytic
action of the isolated PMFs, flumazenil, a selective antagonist
of GABAA receptor was administered at the dose of 2.5 mg/kg
(i.p.), 15min before the administration of isolates or diazepam
in elevated plus maze test (Aragão et al., 2006). After 60min
of isolated PMFs and 30min of diazepam employment, the
experimental mice were placed on the central square of maze
facing to the close arm. Thenumber of entries and time spent in
close and open arms was recorded for 5min and% open arm time
and entries were calculated as stated in elevated plus maze test.
Data Analysis
All results have been shown as median (n = 6) with range (min-
max). The area under the curve (AUC) response was calculated
by trapezoidal rule as an expression of the intensity of the effect.
Data analysis was performed using Kruskal Wallis followed by
Mann-Whitney test at the levels of significance ranging from
p< 0.05 to 0.001 by SPSS 22 (IBM, USA).
RESULTS
Acute Toxicity
Oral treatment of selected doses for compounds 1–4 did not
cause any abnormal effects or mortality during 14 days of
observation. In addition, administration of PMFs 1–4 did not
produce any injuries, sign of abnormalities and significant
differences to the gross weight of the vital organs or body
(Table 1) in animals.
Acetic Acid-Induced Writhing
Compounds 1–4 increased writhing onset time (Figure 2A) as
well as diminished the writhing episodes (Figure 2B) induced by
acetic acid. The effects were significant (p < 0.01) for maximum
experimental doses of compound 1, 2 and 4 and all doses of
compound 3 compared to control group. The onset time of
writhing for compound 3was found as 307.34 s (294.25–343.36 s)
at the dose of 25 mg/kg b.w. which was longer than diclofenac
236.95 s (224.22–247.19 s). Compounds 1, 2, and 4 (25 mg/kg
b.w.) could show maximum increase of onset time of writhing
from 227.64 s (206.24–244.65 s) (showed by control group) to
281.62 s (268.20–296.93 s), 261.93s (248.92–274.38 s) and 278.17s
(262.41–285.34 s) as well as reduction of total number of writhing
from 116.00 (101.00–119.50) (induced by control group) to
79.20 (66.50–84.50), 87.00 (66.50–91.50) and 77.50 (74.50–
91.00), respectively. Compound 3 caused the highest reduction
of writhings [51.50 (43.50–56.50)] at the dose of 25 mg/kg b.w.
than the other PMFs. Maximal of the effect was found for
diclofenac [46.50 (35.00–58.00)]. The inhibition of total writhing
episodes was dependent on dose and maximum inhibition of
59.77, 31.68, 24.59, 54.90, and 29.29% was seen for diclofenac and
compounds 1–4, respectively. In this experiment, glibenclamide
(Gbc) treated mice could not produce any significant differences
of writhing onset time [218.95s (188.47–247.32 s)] (Figure 2A)
and writhing episodes [111.50 (102.50–115.00)] (Figure 2B) with
respect to control group mice. However, pre-treatment of Gbc
significantly (p < 0.01) diminished the effect of compounds 1–4
(25 mg/kg) on writhing protection by 9.96, 0.40, 28.02, and 7.41%
respectively. The significant effect of diclofenac, experimental
compounds 1–4 as well as pre-treatment of Gbc on writhing
onset time and writhing at multiple time intervals are presented
in Supplementary Tables 1, 2.
Hot Plate
The hot plate experiment showed that orally treated mice
with compounds 1–4 significantly (p < 0.01) produced
analgesia against thermal threshold compared to control
group (Figure 3A). The effect was dose reliant and significant
from 45min onwards for all the compounds. However,
Compound 3 showed maximum thermal analgesia at the
dose of 25 mg/kg b.w. at all the observation sessions
compared to other experimental PMFs. Morphine (5 mg/kg
b.w., i.p.) also exhibited the nociceptive protection effect over
the experimental session and the effect was maximum by
26.69 (21.01–40.85) to 57.61 (44.22–74.64)% at the earlier
experimental period (30–60min). Compound 1 showed more
potent effect than morphine at the dose of 25 mg/kg b.w.
in later from 90 to 120min by 50.74 (42.21–53.99) to 52.67
(33.38–58.03)%, respectively. The AUC response (Figure 3B)
showed that morphine and compounds 1–4 significantly (p <
0.01) produced 20.62, 14.87, 10.20, 17.53, 15.49 times higher
thermal protection compared to control group respectively.
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TABLE 1 | Effect of oral treatment of compounds 1–4 on gross changes of the body and vital organs of mice.Q5
Treatment Organ weight [relative organ weight in %]
Body weight Liver Kidneys Lungs Heart Spleen
Vehicle (10 mL/kg) 22.38 (20.10–24.83) 1.53 (1.39–1.74)
[6.90]
0.17 (0.14–0.19)
[0.74]
0.23 (0.20–0.27)
[1.03]
0.12 (0.10–0.14)
[0.53]
0.14 (0.12–0.17)
[0.63]
1 (12.5 mg/kg) 22.05 (20.68–24.80) 1.56 (1.43–1.70)
[6.96]
0.16 (0.13–0.18)
[0.69]
0.21 (0.18–0.26)
[0.95]
0.12 (0.09–0.15)
[0.53]
0.15 (0.11–0.17)
[0.64]
1 (25 mg/kg 22.65 (20.73–23.54) 1.56 (1.43–1.62)
[6.91]
0.16 (0.14–0.18)
[0.71]
0.22 (0.19–0.25)
[0.98]
0.13 (0.10–0.14)
[0.55]
0.13 (0.12–0.16)
[0.61]
2 (12.5 mg/kg) 23.18 (22.12–24.55) 1.60 (1.54–1.70)
[6.87]
0.17 (0.14–0.18)
[0.70]
0.26 (0.22–0.28)
[1.09]
0.13 (0.12–0.14)
[0.55]
0.16 (0.13–0.16)
[0.64]
2 (25 mg/kg) 21.09 (20.02–24.31) 1.45 (1.36–1.75)
[6.92]
0.15 (0.13–0.17)
[0.68]
0.21 (0.18–0.26)
[0.97]
0.13(0.11–0.15)
[0.58]
0.14 (0.11–0.16)
[0.62]
3 (12.5 mg/kg) 23.31 (20.11–23.88) 1.59 (1.50–1.66)
[7.01]
0.16 (0.13–0.18)
[0.70]
0.26 (0.20–0.27)
[1.08]
0.13 (0.10–0.14)
[0.54]
0.15 (0.11–0.18)
[0.65]
3 (25 mg/kg 21.16 (20.61–22.48) 1.48 (1.45–1.50)
[6.95]
0.15 (0.12–0.16)
[0.69]
0.22 (0.21–0.24)
[1.04]
0.13 (0.11–0.14)
[0.60]
0.14 (0.12–0.16)
[0.65]
4 (12.5 mg/kg) 24.24 (23.41–24.86) 1.69 (1.62–1.75)
[7.00]
0.19 (0.16–0.21)
[0.77]
0.26 (0.23–0.28)
[1.06]
0.14 (0.12–0.16)
[0.57]
0.17 (0.14–0.18)
[0.68]
4 (25 mg/kg 21.95 (20.32–24.36) 1.52 (1.43–1.71)
[6.93]
0.18 (0.16–0.22)
[0.81]
0.22 (0.19–0.25)
[0.98]
0.13 (0.11–0.15)
[0.56]
0.15 (0.13–0.17)
[0.65]
Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-
trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone. Relative organ weight (%) = [(organ weight/ body weight)] × 100. Values were not significant (p is
not ≤ 0.05) when compared to control group.
FIGURE 2 | Effect of polymethoxyflavones (PMFs) of N. plumbaginifolia in acetic acid-induced writhing test. The panel shows effect on writhing onset (A), total
number of writhing (B). Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin;
3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone, Gbc = glibenclamide. *p < 0.01 compared to
control group; a,b,c,d,ep < 0.01 compared to 1 (25 mg/kg), 2 (25 mg/kg), 3 (25 mg/kg), and 4 (25 mg/kg), respectively.
Naloxone pre-treatment reverted the antinociceptive action
of compounds 1–4 and morphine significantly (p < 0.05),
where it itself could not induce any significant differences in
thermal protection with respect to control group. The effect
of compounds 1–4, morphine and naloxone pre-treatment
on the latency time was also significant (p < 0.05) at
different experimental periods as shown in Supplementary
Table 3.
Tail Immersion
Oral ingestion of compounds 1–4 caused the thermal pain
protection in tail immersion test (Figures 4A,B). However,
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FIGURE 3 | Effect of compounds 1–4, morphine and pre-treatment of naloxone in hot plate test. (A) Maximal percent of analgesic effect (% MPE) of compounds 1–4,
morphine and antagonist effect of naloxone. (B) Area under the curve (AUC 0–120min) response of the compounds 1–4, morphine and pre-treatment of naloxone.
Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-
dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone, NLX = naloxone. *p < 0.01, compared to control group.
a,b,c,d,ep < 0.05, compared to morphine (5 mg/kg), 1 (25 mg/kg), 2 (25 mg/kg), 3 (25 mg/kg), and 4 (25 mg/kg), respectively.
FIGURE 4 | Effect of compounds 1–4, morphine and pre-treatment of naloxone in tail immersion test. (A) maximal percent of analgesic effect (% MPE) of compounds
1–4, morphine and antagonist effect of naloxone. (B) area under the curve (AUC 0−120 min) response of the compounds 1–4, morphine and pre-treatment of
naloxone. Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-
dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone, NLX = naloxone. *p < 0.01, compared to control group.
a,bp < 0.01, compared to morphine (5 mg/kg) and 3 (25 mg/kg) respectively.
only compound 3 and morphine could approach the statistical
significance (p < 0.01). Compound 3 showed dose-dependent
protection in thermally induced pain and the effect was
statistically significant (p < 0.01) from 45min onwards for all
experimental doses. Morphine (5 mg/kg b.w., i.p.) exhibited
significant reduction in thermal nociception for all observational
sessions while the maximal effect was seen for compound 3 at
the dosage of 25 mg/kg b.w. by 20.35 (14.80–25.45)% on 120min
than it [13.30 (6.65–21.34)%] (Figure 4A). The AUC0−120 min
response demonstrated that thermal nociceptive protection by
morphine and compound 3 at 12.5 and 25 mg/kg b.w. was
11.91, 3.00, and 4.87 times greater and statistically significant
(p< 0.01) with respect to control group respectively (Figure 4B).
Naloxone treated animals could not produce any significant effect
compared to control animals. Naloxone pre-treatment reversed
the percent analgesic as well as AUC0−120 min effect of morphine
and compound 3 (Figures 4A,B). Morphine and compound 3
and pre-treatment of naloxone also caused significant differences
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(p < 0.01) in thermal latency time at multiple observational
periods compared to control group as shown in Supplementary
Table 4.
Formalin-Induced Nociception and Paw
Edema
The treatment of experimental PMFs 1–4 (p.o.) and morphine
(i.p.) diminished the formalin induced early and late phase
nociceptive responses as shown in Table 2. The effect was
significant (p < 0.05) for both phases by morphine and
experimental PMFs (1–4). All test samples produced the highest
protection of nociception at the maximum dose (25 mg/kg b.w.)
and their effect was dose dependent. The maximum inhibition
was produced by morphine (5 mg/kg b.w.) where the effect of
compound 3 was higher compared to other test samples at both
phases. In addition, the inhibition of nociceptive responses was
stronger at late phase for morphine and all test compounds.
The data for time vs. nociceptive effects of morphine, and
compounds 1–4 treatments on formalin-induced nociception
are depicted on Supplementary Figures 1A–D. Treatment of
morphine and compound 1, 3 and 4 could also significantly
(p < 0.05) reduce the formalin-induced paw edema at all
experimental doses (Table 2). Treatments with exoticin (2) could
not approach the statistical significance of the effect. The
maximal inhibition of edematogenic response was exhibited
by morphine (58.48%) where compound 4 showed highest
response (43.25%) with respect to other PMFs at the dose of
25mg/kg b.w.
Carrageenan-Induced Paw Edema
The subplantar injection of carrageenan to the control group
mice caused gradual increase in paw edema from 1 to 5 h,
which decreased at 6 h as shown in Table 3. Mice treated with
experimental PMF 1, 3 and 4 at all test doses caused significant
(p < 0.05) reduction of paw edema from 3 to 6 h compared to
control group. Compound 3 at the dose of 25mg/kg b.w., p.o. and
diclofenac (10 mg/kg b.w., i.p.) exhibited significant reduction
as well as percent inhibition of paw edema from 1 h to end of
the experimental period. PGE2 content (equivalent to OD) of
diclofenac and PMF 1, 3 and 4 treated mice were significantly
(p < 0.01) less than thecontrol group. Exoticin (2) could neither
inhibit edematogenic syndrome nor PGE2 content by any of the
experimental dose. The inhibition of paw edema throughout the
entire experimental time and reduction of PGE2 content was
maximum by diclofenac where compound 3 showed highest at 25
mg/kg b.w. compared to other tested PMFs (Table 3). The result
also showed that there was dose effect for all tested compounds.
Hole Cross
The treatment of experimental compounds 2, 3 (p.o) and
diazepam (i.p.) caused the decrease of movement of mice in
the hole cross test compared to control group mice (Table 4).
However, the effect was significant (p < 0.05) for compound
2 and 3 at the dose of 25 mg/kg b.w. Diazepam (1 mg/kg
b.w.) and compound 2 (25 mg/kg b.w.) administration produced
significant inhibition of movement at all experimental periods
where the effect was maximum by exoticin at 30min and from
TABLE 2 | Effect of morphine, compounds 1–4 in formalin-induced nociception and paw edema test.
Treatment Dose (mg/kg) Total responses time (s) Paw edema
(1 in mm)
after 5 h
% inhibition
Early phase
(0–10min)
% inhibition Late phase
(11–60min)
% inhibition
Vehicle – 209.21
(165.55–225.36)
– 471.10
(395.21–587.97)
– 1.45
(1.32–1.65)
–
Morphine 5 41.70**
(38.01–45.10)
80.08 17.99**
(10.41–24.40)
96.18 0.60**
(0.33–0.91)
58.48
1 12.5 190.17
(170.35–205.85)
9.10 433.05
(366.27–484.51)
8.08 1.08**
(0.83–1.26)
25.61
1 25 146.95**
(134.69–161.44)
29.76 322.66**
(271.24–346.27)
31.51 1.05**
(0.86–1.10)
27.34
2 12.5 209.80
(189.05–231.63)
−0.28 443.17
(379.02–502.71)
5.93 1.23
(1.05–1.63)
14.88
2 25 182.83*
(165.36–204.96)
12.61 382.31*
(337.14–443.45)
18.15 1.19
(0.97–1.64)
17.65
3 12.5 135.65*
(116.81–171.60)
35.16 247.69*
(160.92–267.41)
47.42 0.91**
(0.84–1.14)
37.02
3 25 86.67**
(73.53–113.55)
58.57 160.45**
(141.55–226.59)
65.94 0.83**
(0.67–1.04)
42.91
4 12.5 170.57*
(157.06–186.42)
18.47 357.35*
(269.52–437.84)
24.15 0.99**
(0.92–1.06)
31.49
4 25 132.12**
(116.08–149.21)
36.85 236.85**
(186.05–392.11)
49.72 0.82*
(0.48–1.71)
43.25
Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-
trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone. *, **p < 0.05 and p < 0.01, compared to control group, respectively.
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90 to 120min with respect to other experimental compounds.
Compound 3 could cause significant inhibition during the 60–
90min interval. In contrast, compound 1 and 4 could not
produce any significant differences in effect at any tested dose
compared to control group (Table 4).
Open Field
Compounds 2 and 3 (25mg/kg b.w., p.o.) and diazepam (1mg/kg
b.w., i.p.) treated mice showed significant (p < 0.05) reduction
in the number of square crossings 40.50 (34–50), 44.50 (39–
55), 29.50 (25–46) by 40.88, 35.04, and 56.93 %, respectively
compared to control group mice [68.50 (58–76)] (Figure 5C).
Any significant alteration of the locomotor action was absent for
compound 1 and 4 at any tested dose. The plant PMF 1, 3, 4
and diazepam caused significant (p < 0.05) increase of entries
in central squares (Figure 5A). However, the effect was reduced
due to the increase in the dose of experimental PMFs. Exoticin
(2) treated mice did not exhibit significant increase in central
square entries at 12.5 [13.00 (8–20)] and 25 mg/kg b.w. [8.50
(6–13)] compared to control group mice [11.00 (7–15)].
Compounds 1, 3, and 4 (12.5 mg/kg b.w.) and diazepam
treatment showed highest number of entries of central squares
[22.00 (18–27), 20.50 (17–29), 23.50 (18–33), and 16.00 (14–
29)] (Figure 5A) by 35.95 (27.27–43.55), 32.74 (30.36–39.19),
39.83 (37.50–49.25), and 57.75 (44.12–64.00)%, respectively
(Figure 5B). In addition, percent of entries of central squares
by the treatments was also significant (p < 0.05) compared
to control group [16.67 (11.84–22.06)%]. Diazepam treatment
caused maximum inhibition of a total number of square entries
but an increase of percent of entries of central squares.
Elevated Plus Maze
As illustrated in Figures 6A–C, PMF 1, 3, 4 (p,o) and diazepam
(i.p.) treatment significantly (p < 0.05) increased the entries,
percent entries as well as exploration time in open arms effects
of mice with respect to control group mice in elevated plus
maze test. The results also showed that effects of experimental
PMFs were decreased for the increased of doses. Compound
1, 3, 4 (12.5 mg/kg b.w.) and diazepam produced maximum
number of open arms entries [9.50 (6–12), 8.00 (7–9), 11
(7–12) and 8.50 (4–12)], (Figure 6A), by 45.34 (38.10–60.00),
48.69 (38.89–57.14), 56.22 (41.18–60.00) and 63.33 (40.00–
75.00)%, (Figure 6B), respectively where vehicle treated mice
showed 4.50 (2–7) by 23.89 (13.64–31.82)%. Experimental
animals exhibited highest open arms spent time at 12.5 mg/kg
b.w. of PMF 1 [40.39 (32.13–59.59)%], 3 [38.13 (34.58–
55.99)%] and 4 [45.11 (37.38–51.87)%] whereas diazepam
treatment (1mg/kg b.w.) demonstrated maximum activity
[56.46 (47.12–68.73)%], (Figure 6C). Compound 2, 3 (25
mg/kg b.w.) and diazepam significantly (p < 0.05) decreased
the total arms entries [10.50 (9–13), 14.00 (12–17), and 14.50
(10–16), respectively] compared to control group [20.50
(14–22)], (Figure 6D). The pre-treatment of flumazenil
significantly (p < 0.05) diminished the effects produced by
diazepam, compound 3 and 4 (Figures 6A–D). However, it
could not produce any significant entries [4.00 (2–5)], percent
entries [21.05 (14.29–23.81)] as well as spent time [17.21
(12.04–22.61)%] in the open arms and total arm entries [19.00
(14–23)] responses of mice by itself with respect to control
group. Flumazenil could not alter the activities of compound
1 and 2 treated groups.
TABLE 4 | Effect of diazepam, compounds 1–4 in hole cross test.
Treatment Dose (mg/kg) Number of hole crossed [% inhibition]
0 min 30 min 60 min 90 min 120 min
Vehicle – 10.50 (8–13) 10.00 (7–12) 8.50 (8–12) 6.00 (5–10) 5.00 (4–8)
Diazepam 1 10.00 (8–13) 7.00* (2–8)
[30.00]
5* (3–6)
[41.18]
3.00* (2–4)
[50.00]
2.50* (2–3)
[50.00]
1 12.5 9.00 (8–12) 8.50 (5–12)
[15.00]
8.50 (6–12)
[0.00]
5.50 (2–9)
[8.33]
5.00 (2–8)
[0.00]
1 25 10.50 (9–14) 8.00 (6–13)
[20.00]
7.50 (5–11)
[11.76]
5.00 (3–7)
[16.67]
4.50 (2–8)
[10.00]
2 12.5 11.00 (10–13) 8.00 (7–9)
[23.53]
6.50 (5–11)
[20.00]
4.50 (3–7)
[25.00]
4.00 (2–6)
[20.00]
2 25 10.50 (6–12) 6.00* (3–7)
[40.00]
5.50* (3–6)
[35.29]
2.50* (1–4)
[58.33]
2.50* (1–4)
[50.00]
3 12.5 10.50 (7–12) 9.50 (3–10)
[5.00]
6.00 (3–8)
[29.41]
4.00 (2–6)
[33.33]
4.00 (2–9)
[20.00]
3 25 12 (9–13) 7.50 (5–10)
[25.00]
4.50* (3–7)
[47.06]
3.00* (2–5)
[50.00]
4.00 (2–6)
[20.00]
4 12.5 11.50 (9–14) 8.50 (6–10)
[15.00]
7.50 (6–9)
[11.76]
5.00 (2–8)
[16.67]
3.50 (2–10)
[30.00]
4 25 10.50 (9–13) 8.00 (5–10)
[20.00]
6.00 (4–11)
[29.41]
4.50 (3–7)
[25.00]
4.00 (3–6)
[20.00]
Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-
trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone. *p < 0.05, compared to control group.
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FIGURE 5 | Ambulatory effect of compounds 1–4 and diazepam in open field test. (A–C) Represents effect of PMFs 1–4 and diazepam treatment on total number of
central squares entries, percent of central squares entries and total number of squares crossed in open field, respectively. Values are presented as median (n = 6) with
range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,
5′,8-hexamethoxy-6,7-methylenedioxyflavone. *p < 0.05, compared to control group.
DISCUSSION
The results of present study revealed antinociceptive activity of
polymethoxyflavone (PMF)- 3,3′,5,6,7,8-hexamethoxy-4′,5′-
methylenedioxyflavone (1), exoticin (2), 6,7,4′,5′-
dimethylenedioxy-3,5,3′-trimethoxyflavone (3), 3,3′,4′,5,5′,
8-hexamethoxy-6,7-methylenedioxyflavone (4) of
N. plumbaginifolia in different central and inflammatory
models of pain. Neuropharmacological studies of the compounds
revealed the possibilities of their anti-anxiety effect. Furthermore,
investigation of possible mechanisms of these effects created an
insight on their pharmacological activities.
The PMFs of N. plumbaginifolia significantly (p < 0.01)
delayed the onset as well as caused the inhibition of writhing
episodes (Figures 2A,B) in the acetic acid-induced writhing test.
This test is a reliable method for the evaluation of central
and peripheral analgesic effect of new agents (Le Bars et al.,
2001). Administration of acetic acid (i.p.) causes liberation
of cyclooxygenase (COX), prostaglandins (PGs), lipoxygenase
(LOX), histamine, serotonin, bradykinin, and cytokinin (TNF-α,
IL-8, IL-1β), in the tissue of visceral fluid. These inflammatory
mediators disrupt as well as increase the permeability of blood
brain barrier (BBB) and excite primary afferent nociceptors
by entering into the dorsal horn of central nervous system
(CNS). This results in a pathological condition of pain, which
is characterized as writhing (Ikeda et al., 2001; Radu et al.,
2013). Therefore, it could be suggested that the PMFs diminished
the release of the acid-induced endogenous inflammatory
mediators. The delayed writhing onset by the PMFs indicates
their interruption in nociceptive signals transduction to primary
afferent nociceptors. In addition, attenuation in the numbers of
acetic writhing episodes, delayed onset time of writhing, might be
attributed to the down-regulation of the inflammatory cytokines
TNF-α, IL-1β, and IL-6 proteins (Yin et al., 2016).
PMFs 1–4 demonstrated significant protection of thermally-
induced pain in the hot plate test (Figures 3A,B). However,
thermal analgesia by compound 3 was significant only in the tail
immersion test (Figures 4A,B). These methods are employed for
the evaluation of centrally acting drugs and can be distinguished
based on their pathway of induction of nociception. The hot
plate test is selective for the supraspinally mediated nociception
whereas tail immersion in hot water induces spinally mediated
nociception (Chapman et al., 1985). Opioid agents involve spinal
(µ1, δ1, κ3) and supraspinal (µ1, δ1, σ2, κ3) receptors for
their analgesic action (Hosseinzadeh et al., 2002; Jinsmaa et al.,
2004, 2005). Therefore, the results indicated that inhibition of
nociception by compound 3 could be associated with both spinal
and supraspinal opioid receptors whereas compound 1, 2 and 4
could involve supraspinal opioid receptors.
Formalin administration in the subplantar region of paw
elicits biphasic nociceptive pain. In the first phase (0–
10min), it causes neurogenic pain by the direct excitation of
unmyelinated and myelinated sensory afferent fibers, especially
C-fibers and releases substance P and bradykinin. The second
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FIGURE 6 | Effect of compounds 1–4, diazepam and pre-treatment of flumazenil in elevated plus maze test. The illustrations represent effect of PMFs 1–4 and
diazepam treatment on (A) total number of open arms entries, (B) percent of central squares entries, (C) percent of open arm time, and (D) total number arm entries
in elevated plus maze. Values are presented as median (n = 6) with range (min-max). 1 = 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone; 2 = exoticin; 3 = 6,
7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone; 4 = 3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone, Flu, flumazenil. *p < 0.05, compared to control
group. a,b,c,d,ep < 0.05, compared to diazepam (1 mg/kg), 3 (12.5 mg/kg), 3 (25 mg/kg), 4 (12.5 mg/kg), and 4 (25 mg/kg) respectively.
phase (11–50min) causes inflammatory pain by the release of
excitatory mediators including histamine, bradykinin, serotonin,
prostaglandins (PGs) in the peripheral tissues and disrupting the
neuronal function of the central dorsal horn. The release of tissue
inflammatory mediators also results in paw edema, which peaks
at 5 h and could be inhibited by the supraspinal inputs of CNS
(Wheeler-Aceto and Cowan, 1991; Tjølsen et al., 1992; França
et al., 2001; Campos et al., 2002; Dai et al., 2002). The formalin-
induced paw edema and licking/biting response of paw may
have related to the release of inflammatory cytokines, p-CASP6,
a-CASP6, TNF-α, IL-1β, and IL-6 proteins (Yin et al., 2016).
Therefore, it could be suggested that the test compounds have
downregulated the inflammatory cytokines. It has been reported
that peripherally acting drugs like acetyl salicylic acid, naproxen,
indomethacin inhibit the release of histamine, bradykinin,
serotonin, prostaglandins (PGs) and attenuate the second phase
pain whereas centrally acting drugs suppresses the nociception
of both phases in formalin test (Tjølsen et al., 1992; França et al.,
2001). PMFs 1, 3, 4 significantly (p< 0.01) reduced the formalin-
induced nociceptive responses of both phases and the effect
was more pronounced in the inflammatory phase. In addition,
they have caused a significant (p < 0.05) reduction of formalin-
induced paw edema (Table 2), which suggested involvement of
supraspinal systems in their antinociceptive action. These results
indicated the central antinociceptive as well as potential anti-
inflammatory effects of the PMFs.
Carrageenan-induced paw edema test is widely used in the
evaluation of the anti-edematogenic effect of the experimental
compound. Subplantar injection of carrageenan produces a
biphasic edematogenic response where serotonin, histamine, and
kinins are released in the first phase (0–1 h), whereas the final
phase (1–6 h) is associated with the release of prostaglandins
(PGs), particularly of their E series by the activation of
cyclooxygenase (COX) in tissues. Kinins provide the continuity
between these inflammatory phases (Morris, 2003; Mothana,
2011). Inducible nitrogen oxide synthase (iNOS) might also be
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involved in the formation of carrageenan-induced paw edema
(Salvemini et al., 1996; Mortada et al., 2017). The findings of the
present study revealed that PMFs 1, 3, and 4 could significantly
reduce carrageenan-induced paw edema (Table 3). Therefore, a
significant decrease of both first and second phase edematogenic
response by compound 3 could be due to the inhibition of
release of serotonin, histamine, and PGs or downregulation of
iNOS production. On the other hand, compound 3 and 4 could
significantly inhibit the second phase edema suggesting their
suppression of release of COX products as well as PGs. It has
been found that PGE2 plays a major role in hyperalgesia, IL-6
production and tissue edema at sites of inflammation (Portanova
et al., 1996). The significant (p< 0.01) reduction of PGE2 content
by the plant PMF 1, 3, and 4 (Table 3) could be attributed to their
anti-edematogenic as well as anti-inflammatory effect.
Previous studies reported that mono and
polymethoxyflavones (PMFs) exert opioid mediated
antinociceptive effect (Thirugnanasambantham et al., 1993;
Pandurangan et al., 2014; Nadipelly et al., 2016). Structure activity
relationships study revealed that the presence of methoxy group
(-OCH3) at 5 or 7 positions on flavone moiety could induce
opioid mediated analgesia (Thirugnanasambantham et al.,
1993). The experimental PMFs of present study also comprises
–OCH3 group at 5 and/or 7 positions. Moreover, results of the
present investigation demonstrated that naloxone pre-treatment
diminished the thermal analgesia of PMFs 1–4 in the hotplate or
tail immersion test (Figures 3, 4). This confirmed the association
of opioid system in the antinociceptive effect of the plant PMFs.
The results also suggested that the effect of PMF 1 and 4 involved
supraspinal, where PMF 3 involved both spinal and supraspinal
opioid receptors.
Drugs acting on the spinal and supraspinal systems (e.g.,
morphine, diazoxide) may involve the ATP sensitive K+
channel (KATP) for their antinociceptive effect. In addition,
antinociceptive effect of diclofenac, ketorolac involves opening
of KATP by increasing the intracellular cyclic guanosine
monophosphate (cGMP) level in tissues. Activation of NO-
cGMP pathway causes the opening of KATP followed by an
eﬄuxof K+ ion, membrane re- or hyper-polarization and
reduces the membrane as well as cellular excitability (Lawson,
1996; Ocaña et al., 2004). Glibenclamide has been reported to
selectively block the ATP sensitive K+ channels without affecting
voltage gated and Ca2+ activated K+ channels (Alves and Duarte,
2002; Jesse et al., 2007). Results of the current study exhibited
that the effects of PMFs 1–4 were significantly reversed by
glibenclamide (Figures 2A,B). Thus, it can be suggested that
the PMFs 1–4 might involve opening of KATP system followed
by reduction of membrane and cellular excitability for their
antinociceptive effect.
Oral treatment of experimental doses did not exert any
toxicity, abnormalities of the organ or cause the death of animals,
which indicated that the selected test doses were safe for the
study. The neurobehavioral study showed that increase in the
dose of the experimental PMFs caused a reduction in locomotor
activity, whereas compounds 2 and 3 produced a significant
(p < 0.05) reduction at a maximal experimental dose (25 mg/kg
b.w.) in the hole cross test (Table 4). The effect was also reflected
by diazepam and in the open field test (Figures 5A–C). However,
compound 3 increased the number as well as the percent of
central squares entries in the open field. As shown by the results,
compounds 1 and 4 also increased the number as well as the
percent of central squares entries in the open field but did not
cause any significant alteration of the locomotor activity. It has
been reported that anxiolytic drugs such as benzodiazepines and
5-HT1A agonists increase central and percent of squares entries
of mice on open field (Prut and Belzung, 2003). The results
indicated that compounds 1, 3, and 4 could possess anxiolytic
effect. Therefore, the plant isolates were subjected to evaluate
anxiolytic activity using elevated plus maze test.
Elevated plus maze is a commonly applied method for the
evaluation of anxiolytic activity of new agents (Dawson and
Tricklebank, 1995) and it is validated for both rodents and
mice (Pellow et al., 1985; Lister, 1987). The apparatus contains
two open and closed arms. Animals show extreme aversion to
exploring in the open arms. The indexes of anxiety- exploration
time and number of entries in open arms are sensitive to the
drugs that act on benzodiazepine as well as GABAA receptor
sites. These drugs increase the percent of open arm frequencies as
well as exploration time and decreases total arm entries (Pellow
et al., 1985; Griebel et al., 1996). The results of the experiment
showed that PMFs 1, 3, 4 and diazepam significantly increased
the percent of exploration time and frequency of entries in
open arms (Figures 6B,C). These effects could be attributed to
their anxiolytic activity. However, compounds 1 and 4 did not
cause any significant reduction of total number of entries at the
experimental doses, where compound 3 at the maximal dose (25
mg/kg) and diazepam produced significant (p< 0.05) reductions
(Figure 6D). Flumazenil, a selective benzodiazepine antagonist
of GABAA receptor, significantly (p < 0.05) diminished the
effects of compounds 3 and 4. This confirmed the involvement of
GABAA receptor in their anxiolytic activity. The results showed
that flumazenil could not attenuate the anxiolytic effect of PMF
1, suggesting a different mechanism of action. Experimental
results also demonstrated that an increase of dose reduced the
anxiolytic effect of the PMFs. Drugs acting on benzodiazepine
system has been reported to significantly decrease the locomotor
function (Prut and Belzung, 2003). The effects could be due to
the reduction of locomotor activity which are evident in the hole
cross (Table 4) and open field test (Figure 5) results.
Overall, applications of N. plumbaginifolia in the treatment
of different painful conditions are evident in traditional
systems of medicine and analgesic action along with anxiolytic
effects of its crude extract have already been justified. This
investigation determined that bioactive compounds of
the plant could be related to its actions and justify the
ethnopharmacological importance of the plant. The results
of the present investigation revealed the antinociceptive
potential of the experimental PMFs of N. plumbaginifolia,
where 3,3′,5,6,7,8-hexamethoxy-4′,5′-methylenedioxyflavone
(1) 6,7,4′,5′-dimethylenedioxy-3,5,3′-trimethoxyflavone (3) and
3,3′,4′,5,5′,8-hexamethoxy-6,7-methylenedioxyflavone (4)
produced significant, dose-dependent effect. The antinociceptive
action of the test compounds involved opioid receptor, ATP-
sensitive K+ channel as well as suppression of inflammatory
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mediators such as PGs, COX, LOX. Although the PMFs
have been administered intragastrically and standard drugs
intraperitoneally, the effect of compound 3 was greater
than the respective standard drug in hot plate and acetic
acid tests to some extent (% MPE and onset of writhing,
respectively) for the positive response which could be considered
a significant finding. Evaluation of neuropharmacological
activities aided the elucidation of their anxiolytic activity.
The study also demonstrated anxiolytic-like action involving
benzodiazepine receptors without altering the locomotor
responses at experimental doses. However, direct modulation
of the receptors and nociceptive mediators by the experimental
PMFs will be a greater part of interest. Considering the present
findings into account, it may suggest that the PMFs of N.
plumabginifolia could be suitable candidates for the development
of analgesics as well as anxiolytic agents.
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